AU2015240834B2 - Humanized pertussis antibodies and uses thereof - Google Patents

Humanized pertussis antibodies and uses thereof Download PDF

Info

Publication number
AU2015240834B2
AU2015240834B2 AU2015240834A AU2015240834A AU2015240834B2 AU 2015240834 B2 AU2015240834 B2 AU 2015240834B2 AU 2015240834 A AU2015240834 A AU 2015240834A AU 2015240834 A AU2015240834 A AU 2015240834A AU 2015240834 B2 AU2015240834 B2 AU 2015240834B2
Authority
AU
Australia
Prior art keywords
antibody
seq
humanized
identity
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015240834A
Other languages
English (en)
Other versions
AU2015240834A1 (en
Inventor
Jennifer MAYNARD
Annalee Nguyen
Eduardo Padlan
Ellen Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Theriva Biologics Inc
Original Assignee
The University of Texas System
Synthetic Biologics Inc
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System, Synthetic Biologics Inc, The University of Texas at Austin filed Critical The University of Texas System
Publication of AU2015240834A1 publication Critical patent/AU2015240834A1/en
Application granted granted Critical
Publication of AU2015240834B2 publication Critical patent/AU2015240834B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1225—Gram-negative bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015240834A 2014-03-31 2015-03-31 Humanized pertussis antibodies and uses thereof Ceased AU2015240834B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461973141P 2014-03-31 2014-03-31
US61/973,141 2014-03-31
US201462046403P 2014-09-05 2014-09-05
US62/046,403 2014-09-05
PCT/US2015/023715 WO2015153685A1 (en) 2014-03-31 2015-03-31 Humanized pertussis antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2015240834A1 AU2015240834A1 (en) 2016-09-15
AU2015240834B2 true AU2015240834B2 (en) 2020-02-27

Family

ID=54241237

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015240834A Ceased AU2015240834B2 (en) 2014-03-31 2015-03-31 Humanized pertussis antibodies and uses thereof

Country Status (8)

Country Link
US (3) US9512204B2 (enExample)
EP (1) EP3126385B1 (enExample)
JP (1) JP6588922B2 (enExample)
CN (1) CN106459183B (enExample)
AU (1) AU2015240834B2 (enExample)
CA (1) CA2941152C (enExample)
ES (1) ES2755957T3 (enExample)
WO (1) WO2015153685A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2752396A1 (en) * 2010-09-17 2012-03-17 Board Of Regents, The University Of Texas System Pertussis antibodies and uses thereof
ES2755957T3 (es) * 2014-03-31 2020-04-24 Univ Texas Anticuerpos de tos ferina humanizados y usos de los mismos
JP6805428B2 (ja) * 2014-04-27 2021-01-06 フェイムウェイヴ リミテッド Ｃｅａｃａｍ１に対するヒト化抗体
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
CN107663240B (zh) * 2016-07-29 2021-01-12 中国人民解放军第四军医大学 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
US10538579B2 (en) * 2016-08-15 2020-01-21 Board Of Regents, The University Of Texas System Bispecific pertussis antibodies
WO2018035107A2 (en) * 2016-08-15 2018-02-22 Board Of Regents, The University Of Texas System Stabilized pertussis antibodies with extended half-life
CN119265240A (zh) 2017-10-20 2025-01-07 弗莱德哈钦森癌症中心 用以产生被遗传修饰来表达所选抗体的b细胞的系统和方法
WO2021000886A1 (zh) * 2019-07-01 2021-01-07 苏州康宁杰瑞生物科技有限公司 百日咳毒素结合蛋白
KR20240167591A (ko) * 2023-05-18 2024-11-27 한국과학기술연구원 항-엔도글린 항체 및 이의 용도
CN121800914A (zh) * 2025-11-28 2026-04-07 北京生物制品研究所有限责任公司 特异性结合百日咳毒素的单克隆抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120244144A1 (en) * 2010-09-17 2012-09-27 Board Of Regents, The University Of Texas System Pertussis antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1223529B (it) 1987-12-18 1990-09-19 Sclavo Spa Epitopo immunodominante protettivo contenuto nella subunita' s1 della tossina della pertosse
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US7417133B2 (en) * 2004-02-27 2008-08-26 Institut Pasteur Methods for obtaining thermostable enzymes, DNA polymerase I variants from Thermus aquaticus having new catalytic activities, methods for obtaining the same, and applications of the same
US8445650B2 (en) * 2007-09-25 2013-05-21 Thomas Jefferson University Mutant botulinum neurotoxin serotype A polypeptide and uses thereof
WO2014160098A2 (en) * 2013-03-13 2014-10-02 Excelimmune, Inc. Bordetella specific human recombinant antibodies and uses thereof
ES2755957T3 (es) * 2014-03-31 2020-04-24 Univ Texas Anticuerpos de tos ferina humanizados y usos de los mismos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120244144A1 (en) * 2010-09-17 2012-09-27 Board Of Regents, The University Of Texas System Pertussis antibodies and uses thereof

Also Published As

Publication number Publication date
US20170066816A1 (en) 2017-03-09
CA2941152C (en) 2023-09-19
WO2015153685A1 (en) 2015-10-08
US10035846B2 (en) 2018-07-31
CN106459183B (zh) 2020-05-19
US20150353628A1 (en) 2015-12-10
US9512204B2 (en) 2016-12-06
CN106459183A (zh) 2017-02-22
JP2017511140A (ja) 2017-04-20
EP3126385A1 (en) 2017-02-08
US10526400B2 (en) 2020-01-07
ES2755957T3 (es) 2020-04-24
EP3126385A4 (en) 2018-02-21
JP6588922B2 (ja) 2019-10-09
US20180362621A1 (en) 2018-12-20
EP3126385B1 (en) 2019-09-18
AU2015240834A1 (en) 2016-09-15
CA2941152A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
US10526400B2 (en) Humanized pertussis antibodies and used thereof
JP6983205B2 (ja) 二重特異性ｈｉｖ−１中和抗体
JP6697064B2 (ja) ｐＨ範囲で結合性が異なる薬物動態改善のための抗ＴＦＰＩ抗体変異体
CN105968206B (zh) 抗erbb3抗体
US8617548B2 (en) Methods of preventing or treating anthrax using anti-anthrax antibodies
JP2011516041A5 (enExample)
JP6914283B2 (ja) ヒトのがんを治療するための特異的抗ｃｄ３８抗体
EP3946454A1 (en) Aqueous pharmaceutical composition of an anti-il17a antibody and use thereof
US20210332112A1 (en) Stabilized pertussis antibodies with extended half-life
US10538579B2 (en) Bispecific pertussis antibodies
US20250304657A1 (en) Antibodies with novel fc modification combinations that increase antibody function
CN119584995A (zh) 组合疗法
JP7315259B2 (ja) 百日咳毒素結合タンパク質
WO2022122788A1 (en) Multispecific antibodies against severe acute respiratory syndrome coronavirus 2
JP2016527200A (ja) Ｃｄ３７抗体とクロラムブシルの併用
HK40111253A (en) Compositions and methods for anti-pacap antibodies
WO2025056005A1 (zh) 抗tim-3抗体的药物组合物及用途
HK1218128B (en) Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics
NZ744721A (en) Treatment for rheumatoid arthritis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired